Targeting lysosomal pH restores mitochondrial quality control in GBA1-mutant Parkinson’s disease

By afschroeder • June 18, 2026

Sheshadri P, Costa-Besada MA, Fisher A, Kiraly S, Singh K, Kourouzidou I, Blacker TS, Zeng J, Shirihai OS, Grinstaff MW, Duchen MR. Targeting lysosomal pH restores mitochondrial quality control in GBA1-mutant Parkinson's disease. Transl Neurodegener. 2026 Jun 17;15(1):27. doi: 10.1186/s40035-026-00559-z. PMID: 42310725.

Tags: acidic nanoparticles, Endocrinology, GBA1, lysosomal pH, lysosomes, mitochondria, mTORC1, Parkinson’s disease, Publications

Primary Hyperparathyroidism-Downstream Consequences of Untreated Disease

Yeh MW. Primary Hyperparathyroidism-Downstream Consequences of Untreated Disease. JAMA Surg. 2026 Jul 29. doi: 10.1001/jamasurg.2026.3047. Epub ahead of print. PMID: 42525393.

DGAT1-associated lipid-retinoid dysregulation correlates with metabolic impairment in the RPE of Stargardt disease

Dave A, Ng ESY, Jiang Z, Hu J, Tatang J, Paniagua A, Doeve J, Parikh S, Williams KJ, Stiles L, Radu RA. DGAT1-associated lipid-retinoid dysregulation[...]

Correction to: Consensus and Controversies about Diagnosing GH deficiency – A Delphi Survey by the GH Research Society

Radovick S, Arlien-Søborg MC, Boguszewski MCS, Bidlingmaier M, Johannsson G, Grimberg A, Ho KKY, Biller BMK, Choong CS, Hoffman AR, Backeljauw P, Boguszewski CL, Bollerslev[...]